Wei Zhang

机构：Harbin Medical University, Heilongjiang University of Chinese Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, Chinese PLA General Hospital, Second Affiliated Hospital of Harbin Medical University, First Affiliated Hospital of Harbin Medical University, PLA Academy of Military Science · ORCID：0000-0003-2971-240X

发表论文 35 篇 · 总被引 132 次 · h-index 5

代表论文

• A first-in-human phase 1 study of simnotrelvir, a 3CL-like protease inhibitor for treatment of COVID-19, in healthy adult subjects (2023 · European Journal of Pharmaceutical Sciences · 被引 27)
• Antiviral effectiveness and survival correlation of azvudine and nirmatrelvir/ritonavir in elderly severe patients with COVID-19: a retrospective real-world study (2024 · EClinicalMedicine · 被引 17)
• Current status of electronic health literacy among pregnant women with gestational diabetes mellitus and their perceptions of online health information: a mixed-methods study (2024 · BMC Pregnancy and Childbirth · 被引 16)
• Plasma circulating tumour DNA is a better source for diagnosis and mutational analysis of IVLBCL than tissue DNA (2024 · Journal of Cellular and Molecular Medicine · 被引 9)
• Circ-10720 as a ceRNA adsorbs microRNA-1238 and modulates ZEB2 to boost NSCLC development by activating EMT (2024 · European journal of medical research · 被引 5)
• Exosomal miR‐20b‐5p Induces EMT and Enhances Progression in Non‐Small Cell Lung Cancer Via TGFBR2 Downregulation (2024 · Journal of Biochemical and Molecular Toxicology · 被引 4)